Resolution of the expert council «Possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders»

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Full Text

Restricted Access

About the authors

A. I. Martynov

Author for correspondence.
Email: abramova@bionika-media.ru

MD, professor, academician of RAS, professor of the Department of hospital therapy No. 1 of A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia, president of Russian Scientific Medical Society of Internal Medicine (RSMSIM), Moscow

Russian Federation

M. M. Tanashyan

Email: abramova@bionika-media.ru

MD, professor, corresponding member of RAS, deputy director for scientific work of Scientific Center of Neurology, Moscow

Russian Federation

A. G. Malyavin

Email: abramova@bionika-media.ru

MD, professor, professor of the Department of phthisiology and pulmonology of A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia, chief freelance pulmonologist of the Ministry of Healthcare of Russia in the Central Federal District, secretary general of RSMSIM, Moscow

Russian Federation

A. N. Bogolepova

Email: abramova@bionika-media.ru

MD, head of the Department of cognitive disorders of Federal Center for Brain and Neurotechnology of FMBA of Russia, professor of the Department of neurology, neurosurgery and medical genetics of the Faculty of general medicine of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow

Russian Federation

N. Y. Borovkova

Email: abramova@bionika-media.ru

MD, first deputy director of the Institute of therapy, professor of the Department of hospital therapy and general medical practice of Privolzhsky Research Medical University of the Ministry of Healthcare of Russia, Nizhny Novgorod

Russian Federation

L. N. Eliseeva

Email: abramova@bionika-media.ru

MD, professor, head of the Department of faculty therapy of Kuban State Medical University of the Ministry of Healthcare of Russia, Chairman of the Krasnodar regional branch of RSMSIM, Krasnodar

Russian Federation

M. V. Zhuravleva

Email: abramova@bionika-media.ru

MD, professor, professor of the Department of clinical pharmacology and propaedeutics of internal diseases of I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University), chief freelance specialist – clinical pharmacologist of the Department of Healthcare of Moscow, Moscow

Russian Federation

V. V. Zakharov

Email: abramova@bionika-media.ru

MD, professor of the Department of nervous diseases and neurosurgery of I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University), Moscow

Russian Federation

N. A. Koryagina

Email: abramova@bionika-media.ru

MD, professor of the Department of polyclinic therapy of Academician E.A. Vagner Perm State Medical University of the Ministry of Healthcare of Russia, vice-president of the Association of Doctors of Internal Medicine of Perm Krai, Chairman of the Perm regional branch of RSMSIM, chief freelance therapist of the Ministry of Healthcare of Perm Krai, Perm

Russian Federation

V. P. Mikhin

Email: abramova@bionika-media.ru

MD, professor, head of the Department of internal medicine No. 2 of Kursk State Medical University of the Ministry of Healthcare of Russia, Kursk

Russian Federation

I. V. Osipova

Email: abramova@bionika-media.ru

MD, professor, head of the Department of faculty therapy and occupational diseases of Altai State Medical University of the Ministry of Healthcare of Russia, Barnaul

Russian Federation

O. D. Ostroumova

Email: abramova@bionika-media.ru

MD, professor, head of the Department of therapy and polymorbid pathology of Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia, Moscow

Russian Federation

A. O. Pozdnyak

Email: abramova@bionika-media.ru

MD, professor, head of the Department of therapy, geriatrics and general medical practice of Kazan State Medical Academy – a branch of Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia, Kazan

Russian Federation

U. S. Portnyagina

Email: abramova@bionika-media.ru

PhD in Medical Sciences, associate professor of the Department of internal medicine and general medical practice (family medicine) of the Faculty of postgraduate training of physicians of M.K. Ammosov North-Eastern Federal University, chief freelance specialist in therapy and general medical practice of the Ministry of Healthcare of the Republic of Sakha (Yakutia), Yakutsk

Russian Federation

M. E. Statsenko

Email: abramova@bionika-media.ru

MD, professor, head of the Department of internal medicine of Volgograd State Medical University of the Ministry of Healthcare of Russia, Volgograd

Russian Federation

V. V. Tyrenko

Email: abramova@bionika-media.ru

MD, professor, head of the Department and Clinic of faculty therapy of S.M. Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation, chief cardiologist of the Ministry of Defense of the Russian Federation, Saint Petersburg

Russian Federation

A. I. Chesnikova

Email: abramova@bionika-media.ru

MD, professor, head of the Department of internal medicine No. 1 of Rostov State Medical University of the Ministry of Healthcare of Russia, chief freelance therapy specialist of the Southern Federal District, Rostov-on-Don

Russian Federation

References

  1. Шальнова С.А., Конради А.О., Баланова Ю.А. с соавт. Какие факторы влияют на контроль артериальной гипертонии в России. Кардиоваскулярная терапия и профилактика. 2018; 17(4): 53–60. Shalnova S.A., Konradi A.O., Balanova Yu.A. et al. What factors do influence arterial hypertension control in Russia. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2018; 17(4): 53–60 (In Russ.)]. http://dx.doi.org/10.15829/1728-8800-2018-4-53-60. EDN: XYUQGT.
  2. Pallares-Carratala V., Ruiz-Garcia A., Serrano-Cumplido A. et al. Prevalence rates of arterial hypertension according to the threshold criteria of 140/90 or 130/80 mmhg and associated cardiometabolic and renal factors: SIMETAP-HTN study. Medicina (Kaunas). 2023; 59(10): 1846. https://dx.doi.org/10.3390/medicina59101846.
  3. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC)and the European Society of Hypertension (ESH). Eur Heart J. 2018; 39(33): 3021–104. https://dx.doi.org/10.1093/eurheartj/ehy339.
  4. Vicario A., Coca A., Gasecki D. et al. Effects of antihypertensive treatment on cognitive decline. ESH Scientific Newsletter. 2019; 20: nr. 73.
  5. Forlenza O., Diniz B., Stella F. et al. Mild cognitive impairment (part 1): Clinical characteristics and predictors of dementia. Rev Bras Psiquiatr. 2013; 35(2): 178–85. https://dx.doi.org/10.1590/1516-4446-2012-3503.
  6. Stijntjes M., Aartsen M., Taekema D. et al. Temporal relationship between cognitive and physical performance in middle-aged to oldest old people. J Gerontol A Biol Sci Med Sci. 2017; 72(5): 662–68. https://dx.doi.org/10.1093/gerona/glw133.
  7. Толкачева В.В., Карапетян Л.В., Хуцишвили Н.И. с соавт. Влияние Мексидола на улучшение когнитивного статуса и параметров качества жизни в составе комплексной терапии пациентов с хронической сердечной недостаточностью II–III функционального класса. Кардиология и сердечно-сосудистая хирургия. 2023; 16(4): 362–373. [Tolkacheva V.V., Karapetyan L.V., Khutsishvili N.I. et al. The effect of Mexidol on the improvement of cognitive status and quality of life parameters in the complex therapy of patients with chronic heart failure II–III functional class. Kardiologiya i serdechno-sosudistaya khirurgiya = Russian Journal of Cardiology and Cardiovascular Surgery. 2023; 16(4): 362–373 (In Russ.)]. https://dx.doi.org/10.17116/kardio202316041362. EDN: TNBOGS.
  8. Gottesman R.F., Albert M.S., Alonso A. et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol. 2017; 74(10): 1246–54. https://dx.doi.org/10.1001/jamaneurol.2017.1658.
  9. Болотова Е.В., Лушпай Т.Ю., Ковригина И.В. Повышение эффективности лечения гипертонической энцефалопатии препаратом Мексидол. Журнал неврологии и психиатрии им. С. С. Корсакова. 2018; 118(4): 61–64. [Bolotova E.V., Lushpay N.Yu., Kovrigina I.V. Improvement of the efficacy of treatment of hypertensive encephalohathy by using Mexidol. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2018; 118(4): 61–64 (In Russ.)]. https://dx.doi.org/10.17116/jnevro20181184161-64. EDN: USBEEW.
  10. Mancia G., Kreutz R., Brunstrom M. et al. 2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023; 41(12): 1874–2071. https://dx.doi.org/10.1097/HJH.0000000000003480.
  11. Бойцов С.А., Баланова Ю.А., Шальнова С.А. с соавт. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014; 13(4): 4–14. [Boytsov S.A., Balanova Yu.A., Shalnova S.A. et al. Arterial hypertension among individuals of 25–64 years old: Prevalence, awareness, treatment and control. By the data from ECCD. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2014; 13(4): 4–14 (In Russ.)]. https://dx.doi.org/10.15829/1728-8800-2014-4-4-14. EDN: SLQTRD.
  12. Кобалава Ж.Д., Конради А.О., Недогода С.В. с соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(3): 149–218. [Kobalava Zh.D., Konradi A.O., Nedogoda S.V. et al. Arterial hypertension in adults. Clinical guidelines 2020. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020; 25(3): 149–218 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2020-3-3786. EDN: TCRBRB.
  13. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398(10304): 957–80. https://dx.doi.org/10.1016/ S0140-6736(21)01330-1.
  14. Shi Y., Thrippleton M., Makin S. et al. Cerebral blood flow in small vessel disease: A systematic review and meta-analysis. J Cereb Blood Flow Metab. 2016; 36(10): 1653–67. https://dx.doi.org/10.1177/0271678X16662891.
  15. Стаценко М.Е., Деревянченко М.В. Роль системного воспаления в снижении эластичности магистральных артерий и прогрессировании эндотелиальной дисфункции у больных артериальной гипертензией в сочетании с ожирением, сахарным диабетом 2 типа. Российский кардиологический журнал. 2018: 23(4): 32–36. [Statsenko M.E., Derevyanchenko M.V. The role of systemic inflammation in decrease of elasticity of magistral arteries and in progression of endothelial dysfunction in patients with systemic hypertension, obesity and type 2 diabetes. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2018: 23(4): 32–36 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2018-4-32-36. EDN: XMHFQD.
  16. Андреева Л.А., Панченкова Л.А., Мартынов А.И. с соавт. Показатели центральной гемодинамики у пациентов с артериальной гипертензией, в том числе в составе метаболического синдрома и в сочетании с субклиническим гипотиреозом. Доктор.Ру. 2018; (4): 48–52. [Andreeva L.A., Panchenkova L.A., Martynov A.I. et al. Central hemodynamic parameters in patients with hypertension, including in metabolic syndrome or with subclinical hypothyroidism. Doctor.Ru. 2018; (4): 48–52 (In Russ.)]. EDN: XPBETJ.
  17. Остроумова Т.М., Кочетков А.И. Мозг и сердце. Non nocere. Новый терапевтический журнал. 2022; (11): 52–60. [Ostroumova T.M., Kochetkov A.I. Brain and heart. Non nocere. Novyy terapevticheskiy zhurnal = Non Nocere. New Therapeutic Journal. 2022; (11): 52–60 (In Russ.)].
  18. Остроумова Т.М., Остроумова О.Д. Важность выявления и диагностики признаков поражения признаков поражения головного мозга при артериальной гипертензии. Non nocere. Новый терапевтический журнал. 2020; (11): 4–5. [Ostroumova T.M., Ostroumova O.D. The importance of identifying and diagnosing signs of damage to signs of brain damage in arterial hypertension. Non nocere. Novy terapevticheskiy zhurnal = Non Nocere. New Therapeutic Journal. 2020; (11): 4–5 (In Russ.)].
  19. Боголепова А.Н. Роль оксидантного стресса в развитии сосудистых когнитивных расстройств. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020; 120(8): 133–139. [Bogolepova A.N. The role of oxidative stress in the development of vascular cognitive disorders. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2020; 120(8): 133–139 (In Russ.)]. https://dx.doi.org/10.17116/jnevro2020120081133. EDN: IJCKPO.
  20. Остроумова О.Д., Парфенов В.А., Остроумова Т.М. с соавт. В. Консенсус экспертов. Влияние антигипертензивной терапии на когнитивные функции. Системные гипертензии. 2021; 18(1): 5–12. [Ostroumova O.D., Parfenov V.A., Ostroumova T.M. et al. Expert consensus. Effect of antihypertensive therapy on cognitive functions. Sistemnyye gipertenzii = Systemic Hypertension. 2021; 18(1): 5–12 (In Russ.)]. https://dx.doi.org/10.26442/2075082X.2021.1.200575. EDN: EXNFNY.
  21. Rouch L., Cestac P., Hanon O. et al. Antihypertensive drugs, prevention of cognitive decline and dementia: A systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs. 2015; 29(2): 113–30. https://dx.doi.org/10.1007/s40263-015-0230-6.
  22. Xu G., Bai F., Lin X. et al. Association between antihypertensive drug use and the incidence of cognitive decline and dementia: A meta-analysis of prospective cohort studies. Biomed Res Int. 2017; 2017: 4368474. https://dx.doi.org/10.1155/2017/4368474.
  23. Ding J., Davis-Plourde K.L., Sedaghat S. et al. Antihypertensive medications and risk for incident dementia and Alzheimer’s disease: A meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol. 2020; 19(1): 61–70. https://dx.doi.org/10.1016/S1474-4422(19)30393-X.
  24. Peters R., Yasar S., Anderson C.S. et al. Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis. Neurology 2020; 94(3): e267–e281. https://dx.doi.org/10.1212/WNL.0000000000008732.
  25. Суслина З.А., Смирнова И.Н., Танашян М.М. с соавт. Мексидол при хронических формах цереброваскулярных заболеваний. Лечение нервных болезней. 2002; 3(3): 28–33. [Suslina Z.A., Smirnova I.N., Tanashyan M.M. et al. Mexidol for chronic forms of cerebrovascular diseases. Lechenie nervnykh bolezney = Treatment of Nervous Diseases. 2002; 3(3): 28–33 (In Russ.)]. EDN: TOLLTP.
  26. Пирадов М.А., Танашян М.М., Домашенко М.А. с соавт. Нейропротекция при цереброваскулярных заболеваниях: поиск жизни на Марсе или перспективное направление лечения? Часть 1. острые нарушения мозгового кровообращения. Анналы клинической и экспериментальной неврологии. 2015; 9(1): 41–50. [Piradov M.A., Tanashyan M.M., Domashenko M.A. et al. Neuroprotection in cerebrovascular diseases: Is it the search for life on mars or a promising trend of treatment? Part 1. Acute cerebrovascular diseases. Annaly klinicheskoy i eksperimental’noy nevrologii = Annals of Clinical and Experimental Neurology. 2015; 9(1): 41–50 (In Russ.)]. EDN: TPSVIN.
  27. Пирадов М.А., Танашян М.М., Домашенко М.А., Максимова М.Ю. Нейропротекция при цереброваскулярных заболеваниях: поиск жизни на Марсе или перспективное направление лечения? Часть 2. хронические формы нарушений мозгового кровообращения. Анналы клинической и экспериментальной неврологии. 2015; 9(3): 10–19. [Piradov M.A., Tanashyan M.M., Domashenko M.A., Maksimova M.Yu. Neuroprotection in cerebrovascular diseases: Is it the search for life on mars or a promising trend of treatment? Part 2. Chronic cerebrovascular diseases. Annaly klinicheskoy i eksperimental’noy nevrologii = Annals of Clinical and Experimental Neurology. 2015; 9(3): 10–19 (In Russ.)]. EDN: VKPNUP.
  28. Iadecola C., Yaffe K., Biller J. et al. Impact of hypertension on cognitive function: A scientific statement from the American Heart Association. Hypertension. 2016; 68(6): e67–e94. https://dx.doi.org/10.1161/HYP.0000000000000053.
  29. Мартынов М.Ю., Журавлева М.В., Васюкова Н.С. с соавт. Окислительный стресс в патогенезе церебрального инсульта и его коррекция. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023; 123(1): 16–27. [Martynov M.Yu., Zhuravleva M.V., Vasyukova N.S. et al. Oxidative stress in the pathogenesis of stroke and its correction. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2023; 123(1): 16–27 (In Russ.)]. https://dx.doi.org/10.17116/jnevro202312301116. EDN: VPHPBW.
  30. Танашян М.М., Лагода О.В., Антонова К.В. Сосудистые заболевания головного мозга: перспективы патогенетической метаболической гемангиокоррекции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015; 115(9): 70–75. [Tanashyan M.M., Lagoda O.V., Antonova K.V. Cerebrovascular diseases: perspectives of pathogenetic metabolic haemangiocorrective treatment. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2015; 115(9): 70–75 (In Russ.)]. https://dx.doi.org/10.17116/jnevro20151159170-75. EDN: VHDFRL.
  31. Воронина Т.А. Мексидол: спектр фармакологических эффектов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2012; 112(12): 86–90. [Voronina T.A. Mexidol: Spectrum of pharmacological effects. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2012; 112(12): 86–90 (In Russ.)]. EDN: PTUPBT.
  32. Щулькин А.В. Современные представления об антигипоксическом и антиоксидантном эффектах Мексидола. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018; 118(12–2): 87–93. [Shchulkin A.V. A Modern concept of antihypoxic and antioxidant effects of Mexidol. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2018; 118(12–2): 87–93 (In Russ.)]. https://dx.doi.org/10.17116/jnevro201811812287. EDN: PPTGEP.
  33. Стаховская Л.В., Шамалов Н.А., Хасанова Д.Р. с соавт. Результаты рандомизированного двойного слепого мультицентрового плацебо-контролируемого в параллельных группах исследования эффективности и безопасности Мексидола при длительной последовательной терапии у пациентов в остром и раннем восстановительном периодах полушарного ишемического инсульта (ЭПИКА). Журнал неврологии и психиатрии им. С.С. Корсакова. 2017; 117(3–2): 55–65. [Stakhovskaya L.V., Shamalov N.A., Khasanova D.R. et al. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with Mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2017; 117(3–2): 55–65 (In Russ.)]. https://dx.doi.org/10.17116/jnevro20171173255-65. EDN: YTSZRV.
  34. Боровкова Н.Ю., Ильина А.С., Спасский А.А. с соавт. Цитопротективная терапия при почечном повреждении у больных острым инфарктом миокарда с подъемом сегмента ST. Кардиология и сердечно-сосудистая хирургия. 2017; 10(1): 38–41. [Borovkova N.Yu., Ilyina A.S., Spassky A.A. et al. Cytoprotective therapy for kidney injury in patients with ST-elevation myocardial infarction. Kardiologiya i serdechno-sosudistaya khirurgiya = Russian Journal of Cardiology and Cardiovascular Surgery. 2017; 10(1): 38–41 (In Russ.)]. https://dx.doi.org/10.17116/kardio201710138-41. EDN: YFSWVT.
  35. Федин А.И., Захаров В.В., Танашян М.М. с соавт. Результаты международного многоцентрового рандомизированного двойного слепого плацебо-контролируемого исследования оценки эффективности и безопасности последовательной терапии пациентов с хронической ишемией мозга препаратами Мексидол и Мексидол ФОРТЕ 250 (исследование МЕМО). Журнал неврологии и психиатрии им. С.С. Корсакова. 2021; 121(11): 7–16. [Fedin A.I., Zakharov V.V., Tanashyan M.M. et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol forte 250 in patients with chronic brain ischemia (MEMO). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2021; 121(11): 7–16 (In Russ.)]. https://dx.doi.org/10.17116/jnevro20211211117. EDN: OBNTNH.
  36. Захаров В.В., Остроумова О.Д., Кочетков А.И. с соавт. Международное многоцентровое рандомизированное двойное слепое плацебо-контролируемое исследование оценки эффективности и безопасности последовательной терапии пациентов с хронической ишемией мозга препаратами Мексидол® и Мексидол® ФОРТЕ 250 (исследование МЕМО): результаты субанализа у пациентов с артериальной гипертонией. Терапия. 2023; 9(1): 145–159. [Zakharov V.V., Ostroumova O.D., Kochetkov A.I. et al. International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol® and Mexidol® FORTE 250 in patients with chronic brain ischemia (MEMO): Subanalysis in patients with arterial hypertension. Terapiya = Therapy. 2023; 9(1): 145–159 (In Russ.)]. https://dx.doi.org/10.18565/therapy.2023.1.145-159. EDN: SPQRTS.
  37. Кочетков А.И., Шаталова Н.А., Клепикова М.В. с соавт. К вопросу о доказательной базе нейропротекторной терапии: фокус на этилметилгидроксипиридина сукцинат. Терапия. 2023; 9(8): 162–172. [Kochetkov A.I., Shatalova N.A., Klepikova M.V. et al. More on the neuroprotectory therapy evidential base: Focus at ethylmethyl hydroxypyridine succinate. Terapiya = Therapy. 2023; 9(8): 162–172 (In Russ.)]. https://dx.doi.org/10.18565/therapy.2023.8.162-172. EDN: EQQUCV.
  38. Захаров В.В., Ткачева О.Н., Мхитарян Э.А., Федин А.И. Эффективность Мексидола у пациентов разных возрастных групп с хронической ишемией головного мозга c когнитивными нарушениями (результаты субанализа международного многоцентрового рандомизированного двойного слепого плацебо-контролируемого исследования МЕМО). Журнал неврологии и психиатрии им. С.С. Корсакова. 2022; 122(11–2): 73–80. [Zakharov V.V., Tkacheva O.N., Mkhitaryan E.A., Fedin A.I. Efficacy of Mexidol in patients with chronic brain ischemia and cognitive impairment of different age groups (results of sub-analysis of the international multicenter, randomized, double-blind, placebo-controlled study of sequential therapy in patients with chronic brain ischemia MEMO). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2022; 122(11–2): 73–80 (In Russ.)]. https://dx.doi.org/10.17116/jnevro202212211273. EDN: ZRBMAD.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. Diagnostic algorithm and classification of vascular cognitive impairment

Download (432KB)
Indexing metadata

Copyright (c) 2024 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies